Track 6: Bone and Soft Tissue Pathology:-

Introduction Of Bone and Soft Tissue Pathology:-
We can only stand and move about because of our bones and soft tissues, which also shield our internal organs.
Our bodies are mostly made of bones, fat, muscle, and connective tissue. These tissues and our health can be significantly impacted by cancer, blood disorders, arthritis, and several illnesses.
The Pathologist’s Position:-
Your doctor may take a biopsy sample and send it to our trained pathologists if they have any reason to believe you may have a disease of the bones or soft tissues.
Following microscopic inspection, we will provide a diagnosis so that your doctor can move forward with the most effective course of action.
Practice Program:-
Each year, 4700 surgical specimens are provided as part of the programme. About 20% of these instances are caused by benign and malignant neoplasms, with the remainder being caused by a range of illnesses such arthritis, infections, metabolic disorders, mechanical issues, circulatory malfunction, and trauma. Immunohistochemistry, electron microscopy, cytogenetics, FISH, and PCR are just a few of the sophisticated assessment techniques that are necessary for a number of neoplasms in addition to traditional light microscopy.
Immunohistochemistry, electron microscopy, and molecular genetics are three of the most often used techniques by the service. Numerous private consult cases that are sought by surgeons and pathologists from around the United States and many other nations are not counted in the number of cases at Mass General.
Achievements in academia and research.
Skull-base tumours:-
More surgical samples from tumours at the skull base are examined by this division than by any other facility. The fact that the Department of Therapy Oncology offers proton beam radiation, which draws patients from all over the world, is the basis for the significant number of referrals.
Chordomas and chondrosarcomas make up the vast majority of skull base tumours. As it relates to their immunoprofile and prognosis, the division has published a number of publications that precisely define the morphology of these tumours. Importantly, these investigations have demonstrated that outside institutions make incorrect diagnoses of chordomas and chondrosarcomas in 37% of cases. The bulk of inaccuracies include misclassifying myxoid chondrosarcoma as chordoma; most of these errors might be avoided by doing immunohistochemistry. This inaccuracy is relevant since chordomas require severe surgical excision but chondrosarcomas do not, and the five-year local control rate for chondrosarcomas is 99% as opposed to 50–60% for chordomas.
The identification of some benign bone tumours that can be mistaken pathologically for chondrosarcomas, called chordomas, and the description of chordoma variations that can be mistaken for benign processes are other significant morphologic research relevant to therapy and prognosis.
In addition to examining a subset of kids with aggressive skull base chordomas, we are now publishing a sizable series of articles on chordomas in kids.
As of late, we have finished a comparative genomic hybridization research on chordomas, which we are currently using to examine chordomas and precursor lesions in ferrets.
Cell cycle controllers and suppressor genes:-
In regard to tumour suppressor genes and cell cycle regulators, the division has also investigated the pathophysiology, diagnosis, and therapeutic strategies of bone and soft tissue malignancies. The NF2 gene may have a role in osteosarcomas, as demonstrated in an animal model by mice with NF2 gene knockouts who had an increased chance of developing the disease.
NF2 mutations in human osteosarcoma, however, were not shown by our investigation. p16, RB, and CDk4 expression in osteosarcomas was the subject of another investigation. This study revealed that p16 abnormalities are present in a significant proportion of osteosarcomas, even those without RB abnormalities, suggesting that this crucial cell cycle regulatory mechanism contributes to the development of osteosarcoma.

Track 6: Bone and Soft Tissue Pathology:-

Submit Your Abstract Here

Subtopics of Bone and Soft Tissue Pathology:-
What is the soft tissue in bones?
What is a skeletal pathology?
Bone and soft tissue pathology fellowship
Bone pathology examples
Tissue pathology test
Soft tissue pathology dental
Bone diseases
Pathology subspecialties

Breast Cancer Association Society:-

  1. Ligue nationale contre le cancer
  2. Institut National du Cancer
  3. Cancer Support France
  4. German Cancer Research Center
  5. Hellenic Cancer Society
  6. Hungarian League Against Cancer
  7. The Iceland Cancer Society
  8. Irish Cancer Society
  9. Cancer Focus Northern Ireland
  10. Israel Cancer Association

Breast Cancer Society Universities:-

  1. Marathwada Cancer Hospital & Research Centre, Maharashtra.
  2. Bhagwan Mahaveer Cancer Hospital & Research Centre, Jaipur
  3. Mohan Das Oswal Cancer Treatment & Research Centre, Punjab.
  4. Rajiv Gandhi Cancer Hospital & Research Institute, Rohini, Delhi
  5. Rajkot Cancer Society, Mr. N.P. Cancer Institute, Gujrat
  6. Regional Cancer Centre, Thiruvananthapuram, Kerala.
  7. Regional Centre for Cancer Research, Adyar, Chennai.
  8. Regional Centre for Cancer Research and Treatment, Cuttack
  9. Rotary Cancer Centre, Kanpur, Uttar Pradesh
  10. Tata Memorial Centre, Mumbai

Breast Cancer Association:-  

  1. Cancer BACUP
  2. Cancer Care Society
  3. Cancer Relief Macmillan Fund
  4. Marie Curie – Cancer Care Charity
  5. Cancer Research UK
  6. Leukaemia Research Fund
  7. Medical Research Council
  8. National Cancer Research Network
  9. National Translational Cancer Research Network
  10. Tenovus

Breast Cancer Companies:-

  2. 3T Biosciences
  3. Oisin Biotechnologies
  4. Faeth Therapeutics
  5. MiRXES
  6. Tmunity Therapeutics
  7. Brooklyn ImmunoTherapeutics
  8. Aelan Cell Technologies
  9. CaroGen
  10. Celularity